Development System

Marina Dobrovolskaia

Email: *********@********.***

Address: **** ******* *******

City: Frederick

State: MD

Zip: 21703

Country: USA

Phone: 301-***-****

Skill Level: Management

Salary Range: $110,000

Willing to Relocate

Primary Skills/Experience:

See Resume

Educational Background:

See Resume

Job History / Details:

Marina A. Dobrovolskaia, Ph.D.

Contact Information:

Work:

Nanotechnology Characterization Lab

SAIC-Frederick, Inc. NCI-Frederick

Frederick, MD 21702

Phone: 301-***-****

e-mail: ******@****.***.***

Home:

4959 Barclay Terrace

Fredercik, MD 21703

Phone: 301-***-****

e-mail: *********@********.***

Education and training:

1990-1995 M.Sc. Biology/Microbiology, V.I. Ulianov-Lenin Kazan State University, Kazan, Russia

1995-1998 Ph.D. Biological Sciences/Experimental Oncology, N.N. Blokhin Cancer Research Center, Moscow, Russia

1998-2000 Postdoctoral Research Fellow, Immunology, ABL Basic Research Program and National Cancer Institute at Frederick, Frederick, MD,

advisor: Dr. Nancy R.Rice

2000-2002 Postdoctoral Fellow, Immunology, Henry M. Jackson Foundation for the Advancement in Military Medicine, Uniformed Services University of Health Sciences, Bethesda, MD and University of Maryland in Baltimore, Baltimore MD,

advisor: Dr. Stefanie N. Vogel

2012 present time M.B.A. Hood College, Frederick MD. Expect graduation in 2015

Professional Experience:

2002-2005 Research Scientist, Immunochemistry Department, PPD Development Inc., Richmond, VA responsible for GLP bioanalytical method development and validation in support of PK/PD and immunogenicity studies; responsible for directing and training of junior staff members

2005-2010 Scientist II, Nanotechnology Characterization Laboratory, SAIC-Frederick Inc., National Cancer Institute at Frederick, Frederick, MD - responsible for establishing assay cascade to provide characterization of nanoparticle compatibility with the components of the immune system; development and validation of in vitro assays for assessing nanoparticle immunotoxicity; direct preclinical immunological characterization of nanoformulations intended for cancer diagnosis and therapy; establish and lead nanoparticle immunotoxicty group; review and manage variety of nanoparticle projects

2010- present Senior Scientist, Nanotechnology Characterization Laboratory, SAIC-Frederick Inc., National Cancer Institute at Frederick, Frederick, MD- responsible for identification and characterization of the immunological responses related to nanomaterials; play an active and highly responsible role in projects directed at characterizing the nanomaterials interaction with the immune system in animal models and in vitro assays; develop assays and analyze resulting data, give presentations at public and scientific forums, interface with government regulatory entities, review project applications and consult industry, academia and government clients on immunotoxicity of nanotechnology platforms for drug delivery; lead a group of scientists and technicians in basic research and preclinical projects; write client reports and manuscripts to summarize research findings.

Areas of expertise: Innate immunity Inflammatory signaling Endotoxin signaling, purification and detection GLP bioanalytical method development and validation for the support of preclinical and clinical PK/PD studies Immunotoxicity of nanoparticles

Professional Society Membership:

1998-2004 International Endotoxin Society

1998-2004- The American Association of Immunologists

2002-present American Association of Pharmaceutical Scientists

2005 present ASTM International

2007-present International Standards Organization

Editorial, standard development and meeting organizing activity:

Active member of ASTM International subcommittee E56 (nanotechnology) and ISO subcommittee TC229 (nanotechnology) WG3 (endotoxin standard) Co-edited special issue Identifying and assessing biomaterial nanotoxicity in translational research for preclinical drug development for Advanced Drug Delivery Reviews Organized international workshop Evaluation of Nanoparticle Immunotoxicity Edited book Immunological properties of engineered nanomaterials

Publications:

1: Crist RM, Grossman JH, Patri AK, Stern ST, Dobrovolskaia MA, Adiseshaiah PP,

Clogston JD, McNeil SE. Common pitfalls in nanotechnology: lessons learned from

NCI's Nanotechnology Characterization Laboratory. Integr Biol (Camb). 2012 Dec

17;5(1):66-73. doi: 10.1039/c2ib20117h. PubMed PMID: 22772974; PubMed Central

PMCID: PMC3499664.

2: Afonin KA, Grabow WW, Walker FM, Bindewald E, Dobrovolskaia MA, Shapiro BA,Jaeger L. Design and self-assembly of siRNA-functionalized RNA nanoparticles for

use in automated nanomedicine. Nat Protoc. 2011 Dec 1;6(12):2022-34. doi:

10.1038/nprot.2011.418. PubMed PMID: 22134126; PubMed Central PMCID: PMC3498981.

3: Dobrovolskaia MA*, Patri AK, Simak J, Hall JB, Semberova J, De Paoli Lacerda

SH, McNeil SE. Nanoparticle size and surface charge determine effects of PAMAM

dendrimers on human platelets in vitro. Mol Pharm. 2012 Mar 5;9(3):382-93. doi:

10.1021/mp200463e. Epub 2011 Nov 10. PubMed PMID: 22026635.

4: Dobrovolskaia MA*, Patri AK, Potter TM, Rodriguez JC, Hall JB, McNeil SE.

Dendrimer-induced leukocyte procoagulant activity depends on particle size and

surface charge. Nanomedicine (Lond). 2012 Feb;7(2):245-56. doi:

10.2217/nnm.11.105. Epub 2011 Sep 30. PubMed PMID: 21957862.

5: Frana A, Aggarwal P, Barsov EV, Kozlov SV, Dobrovolskaia MA*,

Gonzlez-Fernndez . Macrophage scavenger receptor A mediates the uptake of gold

colloids by macrophages in vitro. Nanomedicine (Lond). 2011 Sep;6(7):1175-88.

doi: 10.2217/nnm.11.41. Epub 2011 Jun 15. PubMed PMID: 21675859.

6: Skoczen SL, Potter TM, Dobrovolskaia MA*. In vitro analysis of nanoparticle

uptake by macrophages using chemiluminescence. Methods Mol Biol. 2011;697:255-61.

doi: 10.1007/978-1-60327-198-1_27. PubMed PMID: 21116975.

7: Skoczen SL, Potter TM, Dobrovolskaia MA*. Method for analysis of nanoparticle

effects on cellular chemotaxis. Methods Mol Biol. 2011;697:247-53. doi:

10.1007/978-1-60327-198-1_26. PubMed PMID: 21116974.

8: Neun BW, Dobrovolskaia MA*Qualitative analysis of total complement activation

by nanoparticles. Methods Mol Biol. 2011;697:237-45. doi:

10.1007/978-1-60327-198-1_25. PubMed PMID: 21116973.

9: Neun BW, Dobrovolskaia MA*. Method for in vitro analysis of nanoparticle

thrombogenic properties. Methods Mol Biol. 2011;697:225-35. doi:

10.1007/978-1-60327-198-1_24. PubMed PMID: 21116972.

10: Neun BW, Dobrovolskaia MA*. Method for analysis of nanoparticle hemolytic

properties in vitro. Methods Mol Biol. 2011;697:215-24. doi:

10.1007/978-1-60327-198-1_23. PubMed PMID: 21116971.

11: Aggarwal P, Dobrovolskaia MA*. Gold nanoparticle quantitation via fluorescence

in solution and cell culture. Methods Mol Biol. 2011;697:137-43. doi:

10.1007/978-1-60327-198-1_14. PubMed PMID: 21116962.

12: Potter TM, Dobrovolskaia MA*. Analysis of microbial contamination in

nanoparticle formulations. Methods Mol Biol. 2011;697:131-4. doi:

10.1007/978-1-60327-198-1_13. PubMed PMID: 21116961.

13: Neun BW, Dobrovolskaia MA*. Detection and quantitative evaluation of endotoxin

contamination in nanoparticle formulations by LAL-based assays. Methods Mol Biol.

2011;697:121-30. doi: 10.1007/978-1-60327-198-1_12. PubMed PMID: 21116960.

14: Dobrovolskaia MA*, Neun BW, Clogston JD, Ding H, Ljubimova J, McNeil SE.

Ambiguities in applying traditional Limulus amebocyte lysate tests to quantify

endotoxin in nanoparticle formulations. Nanomedicine (Lond). 2010

Jun;5(4):555-62. doi: 10.2217/nnm.10.29. PubMed PMID: 20528451; PubMed Central

PMCID: PMC2900157.

15: Lo ST, Stern S, Clogston JD, Zheng J, Adiseshaiah PP, Dobrovolskaia M, Lim J,

Patri AK, Sun X, Simanek EE. Biological assessment of triazine dendrimer:

toxicological profiles, solution behavior, biodistribution, drug release and

efficacy in a PEGylated, paclitaxel construct. Mol Pharm. 2010 Aug

2;7(4):993-1006. doi: 10.1021/mp100104x. PubMed PMID: 20481608; PubMed Central

PMCID: PMC2914493.

16: Zolnik BS, Gonzlez-Fernndez A, Sadrieh N, Dobrovolskaia MA*. Nanoparticles

and the immune system. Endocrinology. 2010 Feb;151(2):458-65. doi:

10.1210/en.2009-1082. Epub 2009 Dec 16. Review. PubMed PMID: 20016026; PubMed

Central PMCID: PMC2817614.

17: Chanda N, Kan P, Watkinson LD, Shukla R, Zambre A, Carmack TL, Engelbrecht H,

Lever JR, Katti K, Fent GM, Casteel SW, Smith CJ, Miller WH, Jurisson S, Boote E,

Robertson JD, Cutler C, Dobrovolskaia M, Kannan R, Katti KV. Radioactive gold

nanoparticles in cancer therapy: therapeutic efficacy studies of GA-198AuNP

nanoconstruct in prostate tumor-bearing mice. Nanomedicine. 2010 Apr;6(2):201-9.

doi: 10.1016/j.nano.2009.11.001. Epub 2009 Nov 12. PubMed PMID: 19914401.

18: Yim PB, Clarke ML, McKinstry M, De Paoli Lacerda SH, Pease LF 3rd,

Dobrovolskaia MA, Kang H, Read TD, Sozhamannan S, Hwang J. Quantitative

characterization of quantum dot-labeled lambda phage for Escherichia coli

detection. Biotechnol Bioeng. 2009 Dec 15;104(6):1059-67. doi: 10.1002/bit.22488.

PubMed PMID: 19634184.

19: Dobrovolskaia MA*, Germolec DR, Weaver JL. Evaluation of nanoparticle

immunotoxicity. Nat Nanotechnol. 2009 Jul;4(7):411-4. doi:

10.1038/nnano.2009.175. Epub 2009 Jun 28. PubMed PMID: 19581891.

20: Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA*, McNeil SE. Nanoparticle

interaction with plasma proteins as it relates to particle biodistribution,

biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev. 2009 Jun

21;61(6):428-37. doi: 10.1016/j.addr.2009.03.009. Epub 2009 Apr 17. Review.

PubMed PMID: 19376175.

21: Dobrovolskaia MA*, Patri AK, Zheng J, Clogston JD, Ayub N, Aggarwal P, Neun

BW, Hall JB, McNeil SE. Interaction of colloidal gold nanoparticles with human

blood: effects on particle size and analysis of plasma protein binding profiles.

Nanomedicine. 2009 Jun;5(2):106-17. doi: 10.1016/j.nano.2008.08.001. Epub 2008

Dec 13. PubMed PMID: 19071065.

22: Dobrovolskaia MA*, McNeil SE. Immunological properties of engineered

nanomaterials. Nat Nanotechnol. 2007 Aug;2(8):469-78. doi:

10.1038/nnano.2007.223. Epub 2007 Jul 29. Review. PubMed PMID: 18654343.

23: Dobrovolskaia MA*, Clogston JD, Neun BW, Hall JB, Patri AK, McNeil SE. Method for analysis of nanoparticle hemolytic properties in vitro. Nano Lett. 2008

Aug;8(8):2180-7. doi: 10.1021/nl0805615. Epub 2008 Jul 8. PubMed PMID: 18605701;

PubMed Central PMCID: PMC2613576.

24: Dobrovolskaia MA*, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to

understand nanoparticle interaction with the immune system and its potential

effects on nanoparticle biodistribution. Mol Pharm. 2008 Jul-Aug;5(4):487-95.

doi: 10.1021/mp800032f. Epub 2008 May 30. Review. PubMed PMID: 18510338; PubMedCentral PMCID: PMC2613572.

25: Hall JB, Dobrovolskaia MA, Patri AK, McNeil SE. Characterization of

nanoparticles for therapeutics. Nanomedicine (Lond). 2007 Dec;2(6):789-803.

Review. PubMed PMID: 18095846.

26: Dobrovolskaia MA, Kozlov SV. Inflammation and cancer: when NF-kappaB

amalgamates the perilous partnership. Curr Cancer Drug Targets. 2005

Aug;5(5):325-44. Review. PubMed PMID: 16101381.

27: Kozlov SV, Dobrovolskaia MA, Rice NR, Stewart CL, Vogel SN. A novel

cell-based system for the rapid quantitative evaluation of (anti)-inflammatory

potential of test substances. J Immunol Methods. 2003 Oct 1;281(1-2):51-63.

PubMed PMID: 14580881.

28: Dobrovolskaia MA, Medvedev AE, Thomas KE, Cuesta N, Toshchakov V, Ren T, Cody MJ, Michalek SM, Rice NR, Vogel SN. Induction of in vitro reprogramming by

Toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR

Contact this candidate